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ABSTRACT
At its most elemental, patient-reported outcomes (PRO)
assessment involves asking the patients questions and evalu-
ating their answers. Instrument developers need to be clear
about what they want to know, from whom they want to
know it and why, whether what they learned is credible, and
whether they can interpret what they learned in the context of
the research objectives. Because credible instrument develop-
ment is neither inexpensive nor technically trivial, researchers
must ﬁrst determine that no available measure meets their
research objectives. We suggest that the tasks of either review-
ing current instruments or developing new ones originate
from the same basic premise: PRO assessment requires a
well-articulated conceptual framework. Once deﬁned in the
context of the research objectives, the conceptual framework
needs to be adapted to the population of interest. We
discuss how qualitative methods enrich the conceptual frame-
work and facilitate the technical measurement tasks of item
development, testing, and reduction. We recognize that PRO
assessment stands at a technological crossroads with the
increasingly frequent application of “modern” psychometric
methods and discuss how innovations such as item banks and
computer-adaptive testing will inﬂuence PRO instrument
development. Although items are the essential building blocks
for instruments, scales are the primary unit of analysis for
PRO assessment, and we discuss methods for scoring and
combining them. Finally, PRO assessment is meaningless if the
key ﬁgure chooses not to cooperate. We consider how respon-
dent burden inﬂuences the quality of PRO assessment.
Keywords: assessments, instrument development, patient-
reported outcomes.
Introduction
Perspective
Health-care stakeholders need assurance that patient-
reported outcomes (PRO) data collected from the
instrumentation is credible. “Credibility” should be
judged by two general criteria: Do the data stem from
an instrument that has a theoretically sound concep-
tual framework? Do the data meet necessary and suf-
ﬁcient psychometric standards?
Credible instrument development is neither inex-
pensive nor technically trivial. Researchers providing
information from new instruments must make the case
that none of the available measures meet the research
objectives. Current measures must inadequately ad-
dress the conceptualization of the research question, or
the psychometric evidence must be insufﬁcient, or
both. This article addresses the key points that inves-
tigators wishing to develop new instruments must
cover.
Thoroughly addressing the issue regarding existing
measures is the critical ﬁrst step in instrument devel-
opment. By considering the issues discussed in this
article, researchers may conclude that existing instru-
ments do, in fact, meet their research requirements.
Alternatively, they may have better evidence to support
their decision to invest in new instrument develop-
ment. In either case, investigators will be in a better
position to make an informed choice about how to
proceed.
Importance of a Conceptual Framework
Instrument development proceeds from a conceptual
framework. Developers need to describe the theory
that inﬂuenced choices about the constructs measured.
Despite a large and growing body of literature [1,2]
and a proliferation of PRO instruments (we found
more than 2000 PubMed citations for PRO instrument
development articles since 1995), no single set of nec-
essary and sufﬁcient PRO concepts is universally
accepted. Rothman et al. [3] in this supplement
address the issues involved in establishing conceptual
foundations. Our focus is on the critical role that a
conceptual framework plays in directing PRO instru-
ment development.
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Instrument developers must articulate how a par-
ticular conceptual framework guided their construct
selection, item development, and psychometric testing.
Several examples of well-developed theoretical models
are available, ranging from the community-centered
model that underlies the Medical Outcomes Study
Short Form (SF-36) [4] to utility models that specify
trade-offs between quantity and quality of life [5–7].
The community-centered theory illustrates how the
framework forms the basis for, and predicts the asso-
ciations among, the relevant constructs. The theory
postulates that illness affects a hierarchy of functional
domains, with physical functioning at the base.
Although the physical effects of disease are central
(e.g., affecting mobility, energy, or other domains),
effects are also perceived in more distal domains, such
as psychological and emotional functioning, and ulti-
mately in the performance of social roles [8].
This theoretical framework leads to a multidimen-
sional measurement model that assesses functioning
across a hierarchy of four principal domains: physical,
psychological, social, and symptomatic [9]. In this
model, physical functioning and symptoms are typi-
cally weighted more heavily, and they are expected to
be correlated with other domains, such as psychologi-
cal and role functioning. Furthermore, scores on this
measure should be systematically related to indices of
morbidity, external measures of psychological func-
tioning, and “real time” measures of daily functioning
[10].
Developers need to specify the intended purpose
because the characteristics for PRO instruments
intended for screening or case-load description are dif-
ferent from those developed to evaluate new medical
or behavioral interventions.
Specifying theTarget Population
Because PRO measures are designed to reﬂect the sub-
jective perceptions of the patient, specifying respondent
characteristics is a critical requirement for new in-
strument development. Research indicating differing
health-related quality of life (HRQOL) perceptions––
between patients, nurses, physicians and spouses,
between children and their parents, and between
children and health-care professionals [11–13]––
underscore the importance of taking respondent char-
acteristics into account in instrument development.
Although patients are the preferred respondents, for
some populations a proxy respondent is necessary;
some patients are too young or too old to complete the
measure, some are too ill, and still others have signiﬁ-
cant developmental delay or cognitive impairment that
precludes them from responding. The conceptual
model may call for the perspective of both the patient
and proxy respondent; for example, when assessing
treatment burden on caregivers [14–17] or spouses
[18–21] or when determining the parents’ perspective
of their child’s asthma symptoms.
The underlying framework dictates the manner in
which investigators can incorporate key demographic
variables into the development process. Although age,
sex (and perhaps gender), race and ethnicity, literacy
level, and developmental ability should all be taken
into account when an instrument is being developed,
the approach will differ if the instrument is to
be generalizable or focused. Generalizing to well-
explicated target populations should be distinguished
from generalizing across populations [22]. Both quali-
tative research and subsequent psychometric test-
ing need to incorporate study designs that allow
the developer to detect possible threats to external
validity.
Methods for Specifying Domain Content
The theoretical framework deﬁnes the context for gen-
erating the initial item pool. Developers need to specify
the techniques they employed to produce the item
pool. Appropriate methods include literature and web-
based searches, in-depth interviews and focus groups
with patients (and proxies), and interviews with
experts in the ﬁeld.
Literature Review
Developers need to describe the search strategies
they selected to review journals and bibliographic
databases. Medical databases (e.g., MEDLINE) are
obvious ﬁrst steps, but often PRO instrument develop-
ers overlook other disciplines. The American Psycho-
logical Association’s PsycINFO database [23] covers
the literature in psychology psychiatry, nursing, soci-
ology, education, pharmacology, physiology, linguis-
tics, and other areas. The database encompasses
references and abstracts to more than 1300 journals
and dissertations in more than 30 languages and to
books in the English language.
The International Bibliography of Social Sciences
[24] indexes the information contained in more than
2600 social sciences journals and 6000 books each
year. Coverage includes both core and specialized
material from more than 100 countries in more than
90 languages. Approximately 70% of the records are
in English, and articles in other languages are dis-
played with both the original language title as well as
an English translation. EMBASE: Rehabilitation and
Physical Medicine is an international biomedical
and pharmacological database containing citations
and abstracts to journal literature on rehabilitation of
both physical and mental disorders using physio-
therapy and other therapies [25]. EMBASE contains
more than 10 million records from 1974 to present,
with 500,000 citations and abstracts added annually.
EMBASE features comprehensive coverage of drug
research, pharmacology, pharmacy, pharmacoeco-
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nomics, pharmaceutics and toxicology, human medi-
cine (clinical and experimental), basic biological
research, health policy and management, public,
occupational and environmental health, substance
dependence and abuse, psychiatry, forensic science,
and biomedical engineering and instrumentation.
Special consideration needs to be given to the
potential sources of bias that might emerge from the
literature. For instance, an instrument that is designed
to measure symptoms in chronic obstructive pulmo-
nary disease (COPD) [26] may not be the right instru-
ment if the researcher wants to measure loss of
functionality because of COPD symptoms. Additional
biases may be introduced with the particular choice of
Medical Subject Heading terms used while doing this
literature search. Information gained during this step
should be used to aid in the development of a qualita-
tive discussion guide for preliminary work in the con-
struction of a new measure.
Other Instrument Review
Existing instruments that address the same or related
areas of PRO assessment should be identiﬁed and
reviewed. Existing instruments may not be measuring
speciﬁc domains of interest (e.g., rheumatoid arthritis-
related fatigue). The degree to which some well-
established instruments are accepted for certain
applications may change. For example, the symptom-
speciﬁc Baseline and Transition Dyspnea Indices have
an extensive publication history but faced some criti-
cism during the approval of tiotropium [27].
Several comprehensive instrument review resources
are available to developers. The Mental Measurements
Yearbook Test Reviews On-line [28] covers more than
2000 commercially available educational, personality,
aptitude, neuropsychological, achievement, and intel-
ligence tests. The Behavioral Tests and Measures in the
Health Sciences Resource Guide [29] describes major
resources used to locate materials on psychological or
behavioral questionnaires, surveys, measures, tools,
scales, and instruments as related to the health sci-
ences. Health and Psychosocial Instruments (HaPI)
[30] provides ready access to information on measure-
ment instruments, including questionnaires, interview
schedules, checklists, index measures, coding schemes/
manuals, rating scales, projective techniques, vignettes/
scenarios, and tests in the health ﬁelds, psychosocial
sciences, organizational behavior, and library and
information science.
Qualitative Assessment in Instrument Development
and Selection
Qualitative research is an important component in
PRO instrument development, and may also be a criti-
cal component of selection among existing instru-
ments. Qualitative research needs to be approached
with the same sense of rigor that accompanies quanti-
tative assessment. The use of a semistructured discus-
sion guide, developed from the conceptual framework
and literature review, is essential. The focus group
should be large enough to generate diverse viewpoints,
but small enough to be manageable; Krueger [31]
recommends seven to 10 people per focus group. To
be effective, a trained and experienced professional
should moderate focus groups, and developers should
convene at least three separate groups. PRO research-
ers need to be mindful of several issues that can con-
found the content development during focus groups.
These include: 1) bias inherent in the development of
discussion guide; 2) bias introduced by the discussion
leader; 3) dominance effects; and 4) lack of experience
of group to the concept under investigation.
In-depth Interviews
We endorse in-depth interviews and cognitive debrief-
ing as critical methods in PRO instrument selection
and development. Such focused, one-on-one conversa-
tions with relevant individuals (patients from the
assessment target populations) conducted by trained
staff provide valuable insight into the respondent’s
perception, feelings, and perspectives of the disease
condition. Key to success is anticipating and organiz-
ing the issues that are to be explored. These interviews
provide an opportunity to follow up on questions and
probe for deeper meaning and understanding of the
responses. Instrument developers need to be aware of,
and address, issues that may affect the interview
content. The experience of the ﬁrst few subjects could
bias the line of questioning that the interviewer takes
with subsequent subjects. In-depth interviewing is
time-consuming and resources need to be planned
accordingly. Small samples are not likely to be fully
representative of the target population. Patients should
be considered the primary source of information, espe-
cially when the PRO relates to concepts such as patient
satisfaction and psychosocial function. In-depth inter-
views are critical to both item generation and scale
construction.
Cognitive debrieﬁng, a less time-intensive step, con-
sists of a structured interview that asks patients how
well they understand items of new or existing scales,
how comfortable they are with answering the items,
and how well the items reﬂect their concerns with their
disease or treatment. Cognitive debrieﬁng may be an
iterative process in scale development. Cognitive
debrieﬁng should also be helpful in evaluating a choice
among existing scales where the original scale devel-
opment did not include substantial patient input.
Target Population Surveys
As an effective tool for obtaining patient-level feed-
back of speciﬁc content, target population surveys
present a highly structured series of written questions
that are administered to a large number of persons
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with a speciﬁc disease or condition. They are useful to
describe populations, to assess the prevalence of
behavior and knowledge of populations, and to get a
preliminary quantitative assessment of the concepts
under study. Survey design is important to maximize
the resources invested. Sample sizes depend on the
objectives, and investigators can estimate them from
either preliminary data or the literature. Using
dichotomous data (or creating them from polytomous
data), sample size requirements for the desired level
of precision can be estimated from the proportional
response distribution and the standard error:
N = P(1)P(0)/Std Error2.
Content Analysis of Available Data Sources
Online “blogs” or chat rooms, and other data sources
provide a readily available and inexpensive source for
content analysis. For example, the site Data on the Net
(University of California, San Diego) links to 156 dif-
ferent sites that provide social science data [32]. Most
diseases and medical conditions have user groups,
allowing for sampling content from target popula-
tions. Content can be downloaded and analyzed with
qualitative analysis software (some 20 different pro-
grams are available, including freeware from the
Centers for Disease Control and Prevention, http://
www.cdc.gov/HIV/software/ez-text.htm) to provide
support for domain speciﬁcation. Although informa-
tion gained can be used in the development of PRO
measures, further work is needed to determine what
bias such self-selected samples are likely to contain.
Expert Panels
Both informal and formal consensus methods ought
to be utilized during the PRO instrument development
process. Informal methods––“Three Smart People in a
Room”––often yield valuable guidance from a small
group of content experts. This information can be used
in more formal consensus methods; for example,
Delphi or Nominal Group techniques, where formal
inquiry is interspersed with controlled feedback
[33–36]. In either case, the list of items generated
during the qualitative interview process should be
reviewed by clinicians experienced in treating or man-
aging patients from the disease area in question to
ensure: 1) coverage of signs, symptoms, and other
issues most often reported by patients; and 2) use of
terminology used by patients in the clinic setting.
Adding this step to the development of PRO items
addresses the issue of content validity.
Item Selection:The Construct–Respondent
Interface
Inexperienced instrument developers are tempted to
begin with the items. Previous sections in this article,
as well as other articles in this supplement (e.g.,
Rothman et al. [3]), counsel against this starting point;
instead, we argue for a well-founded theoretical basis
and thorough familiarity with the relevant work in the
area. Only then should an item-pool be developed and
tested.
The conceptual framework determines the item
content; item formatting decisions depend on the
intended uses for the instrument. Kirshner and
Guyatt’s taxonomy [37] of descriptive, evaluative, and
predictive measures is a useful framework. The tech-
nical issues involved in designing and testing items are
covered thoroughly in several psychometric texts (cf.
[38–40]).
Item Response Theory Assessment
Patient-reported outcomes assessment is at a techno-
logical crossroads. As the patient’s role in health-care
decisions becomes more prominent, the technology
available to convey his or her state of health and
well-being is reaching new levels of sophistication. For
a decade or so, social science and educational research-
ers have applied the “modern” psychometric tech-
niques of item banking, item response theory (IRT),
and computer-adaptive testing (CAT) to assessment
development [41], but only relatively recently and with
an accelerating pace have these methods made their
way onto the PRO assessment stage. In June 2004,
the National Cancer Institute and the Drug Informa-
tion Association sponsored a conference entitled
“Advances in Health Outcomes Measurement: Explor-
ing the Current State and Future Applications of Item
Response Theory, Item Banks, and Computerized-
Adaptive Testing,” which represented an important
opportunity for PRO researchers to discuss this
advancement in technology [42].
These developments have important implications
for PRO instrument design. Most applications con-
tinue to rely on static assessment. Researchers have to
balance coverage, precision, speciﬁcity, and respondent
burden. IRT methods have the potential of reducing
the need for additional static instruments to plug gaps
in the PRO assessment spectrum. Several initiatives,
notably the Patient-Reported Outcomes Measurement
Information System project, are addressing the issue
of developing calibrated item banks (http://www.
nihpromis.org). By knowing the precise location of the
item “difﬁculty” (or severity) with respect to the under-
lying latent PRO domain, researchers are able to tailor
instruments that optimize the coverage and precision
with the fewest number of items, thereby addressing
the respondent burden issue as well. Although the goal
of a nationally normed calibrated item bank is still
over the horizon, “local” item banks calibrated to
speciﬁc diseases provide an important interim step in
advancing PRO instrument development and applica-
tion [43].
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Computer-adaptive testing has tremendous poten-
tial for yielding precise PRO assessment quickly and
with signiﬁcantly reduced respondent burden. Al-
though CAT provides technical solutions to many
PRO assessment problems, it is not yet suited to all
applications [44].
Scale Development and Scoring
The item is the unit of analysis in psychometrics, the
scale is most often the unit of analysis in PRO assess-
ment. Although the assumptions underlying the prop-
erties of a scale differ between classical and modern
measurement theory, the objective is the same: the
scale is the building block for the conceptual
framework.
Scales provide the basis for generalizing the results
beyond the speciﬁc content of an item, from “I can
climb one ﬂight of stairs” to mobility, or “I feel down-
hearted and blue” to depression. These conceptual
building blocks require evidence that they are the
optimal combination of items that conveys the con-
ceptual meaning, including internal consistency, con-
vergent and divergent validity, differential item
functioning, and the like. Once the scale has been
established, the individual items are often ignored and
the analysis and interpretation center around anxiety,
pain, sexual functioning, and the like.
Scale scoring lies at the heart of the interpretation
debate. The most frequently asked question of PRO
assessors is “What do these scores mean?” There are
two facets of equal importance to this question: frame
of reference and clinical meaning.
The ﬁrst important facet involves a clear frame of
reference. PRO assessment does not (yet) have a stan-
dard reference. One advantage of the SF-36 is the
existence of national norms. Although many applica-
tions do not involve direct comparisons with national
norms (examining treatment differences between two
agents, for example), consumers of PRO information
often seek to place the results in some larger frame of
reference.
The increasingly common practice of converting all
scale scores to a 0–100 scale is an attempt to address
this issue. One solution, widely used in educational
research and being employed by some PRO research-
ers, is to convert the scales to T-scores, centering the
distribution at a common mean (e.g., 50) and estab-
lishing a common standard deviation (e.g., 10). Addi-
tional items of varying “difﬁculty” or severity can be
included in the scale without affecting the scaling.
The second facet involves “clinical signiﬁcance” or
“minimally important [clinical] differences.” This issue
represents a considerable barrier to widespread accep-
tance of PRO information in health-care research. The
issue has been given careful thought, notably the
“Symposium on the Clinical Signiﬁcance of Quality-
of-Life Measures in Cancer Patients” [45]. Instrument
developers need to include information on minimally
important difference research in the PRO instrument
dossier, including the selection of the approach
(anchor- or distribution-based), as well as the study
design and results.
Summary Scale Development and Scoring
Summary scales, also known as summated rating
scales or Likert summated scales, are a set of questions
(items), all of which are considered to be of approxi-
mately equal value and to which subjects respond with
degrees of agreement or disagreement (intensity). The
score on the questions are either summed or averaged
to yield an individual score per subject [38,46,47].
This idea has been advanced further to create an even
higher-level summary that is a summated scale of two
or more summary scales [48]. Investigators should
develop and use summary scales when they need to
limit the number of outcomes being analyzed (i.e., the
multiple comparison issue), and when the effect being
investigated is considered to be extremely general in
nature and expected to affect several different domains
of quality of life.
The primary goals of creating summary scales are
twofold: ﬁrst, to place an individual somewhere on a
continuum of the construct that is being measured
(e.g., “physical functioning”); and second, to reduce
the number of statistical comparisons required to
analyze the construct without loss of information
[47,48]. Scales often comprise many items to increase
the reliability, precision, and validity of the measure-
ment of the construct. Often, factor analysis or prin-
cipal component analysis are used to evaluate if several
items or scales are measuring the same underlying
construct and could be grouped together. As Ware has
pointed out, psychometrically based summary mea-
sures or aggregated health measures often lead to the
same conclusion [48].
Summated scales belong to the classical psychomet-
ric model of parallel test items. In this approach, devel-
opers make three main assumptions: 1) each item is a
measure of the same underlying construct; 2) the items
have similar statistical properties; and 3) the items
can be easily combined. Adaptive testing may allow
researchers to collect the necessary detail for a sub-
population of interest, while collecting only key items
that are necessary for general population norms are
collected from all subjects. This new approach achieves
the twin goals of minimizing respondent burden and
allowing for complete collection of the attributes that
characterize the subpopulation’s health status.
Necessary and Sufﬁcient Evidence for a “Summary
Scale” in Static Testing
The analytic evidence that investigators typically con-
sider for construction of a summary scale entails either
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factor analysis or principal component analysis. Items
should have the same possible range of score values;
otherwise, variance because of response sets can com-
plicate the interpretation of these analyses. The pattern
of correlations observed between items should support
the conclusion that each item is approximately an
equally good indicator of the same underlying con-
struct. In other words, the summary scale should
account for a substantial amount of the variance
without single items not in the summary scale contrib-
uting to the variance explained. Conﬁrmation of the
variance-explained results in different patient popula-
tions provides further evidence supporting the validity
of the construction of the summary scale. Thus, addi-
tional factor analysis or principal component analysis
should be done in other surveys and should yield the
same amount of explained variance by the summary
scales.
Nevertheless, summary scales constructed of
“symptoms” should be approached with extreme
caution. By their very nature, different symptoms have
differential intensities of effect on patients and their
quality of life. Without weighting the symptoms by
patients’ ratings of importance, one can commit a
grievous error of minimizing a symptom that has an
overwhelming impact on a patient’s quality of life.
Interpretability of Scores
Investigators often ﬁnd it difﬁcult to determine
whether the simplicity and ease of a summary measure
in statistical analysis obscures important change in a
particular domain or area of health-related quality of
life. This problem of interpretation becomes more
complex if population issues are at stake. A case in
point may be whether the elderly differ dramatically
from the general population on a particular health
domain or item but not on a summary scale of general
health.
Consideration of Consumers of Scores:
Patients, Providers, Caregivers, and Regulators
Summary scales are a psychometrically sound
approach that provides consumers with an easy
method of scoring and a readily interpretable score
that has sensitivity and speciﬁcity for a particular
domain. Utility scores or indices, by contrast, are mea-
sures that are aggregated without consideration of the
underlying domains. They have been shown to have
ﬂoor and ceiling effects and low correlations with
other general quality-of-life measures.
Administrative Burden
Investigators need to take account of two main deter-
minants of respondent burden. The ﬁrst is length of
assessment. A second determinant is ease of respond-
ing and patient comprehension of the assessment task,
especially in the context of the trial. Trialists need to
consider whether the assessment “makes sense” to the
patients in terms of what question the trial is trying to
answer.
The most obvious reason to minimize respondent
burden is for patient comfort and convenience. From
the trial perspective, reducing respondent burden is a
major factor in reducing missing data. Respondent
burden is situational. Patients who have long waiting
periods during their clinic visit may be more willing to
spend longer periods completing an assessment. Doing
assessments electronically (computer or interactive
voice response systems) may allow patients to com-
plete longer assessments at home, without the pres-
sures that accompany clinic visits (multiply scheduled
consultations, concern about transport to and from the
clinic, concerns about childcare or returning to a job).
Finally, some patients are just too ill to complete more
than a very short assessment.
Reduction of respondent burden should be a major
consideration in trial design. Assessors need to con-
sider which instruments can answer the trial questions
most parsimoniously. If more than one instrument
needs to be used, then the strategy extends to consid-
eration of the minimal set of instruments in the battery.
If sufﬁcient data exist, a psychometric approach (using
variants of factor analysis) can be used to assure that
only the most trial-relevant questions or measures are
used. Finally, not all assessment instruments may need
to be given at each assessment point. For example, in a
symptom reduction trial, simple ratings of symptom
severity are often used at more frequent points than
measures of function, global quality of life, or satisfac-
tion with treatment.
Respondent burden associated with an assessment
battery is multiplied by the number of assessment
points required by the study design. The more assess-
ment points that are required (longitudinal assess-
ment), the more compact the assessment needs to be.
Often, two important aspects of the trial may help
solve these design questions: 1) how quickly is the
agent of interest expected to have its ﬁrst clinically
meaningful effects; and 2) when is its maximum beneﬁt
expected to be achieved (latency of effect). Longitudi-
nal assessment is required to answer these questions.
The time period(s) in question may be hours, days, or
weeks, or in some cases (relief of traumatic or cancer
pain crisis), even minutes. The severity of the condition
and its implications for the patient drives the need for
rapidly acting interventions. Severe depression is an
example. Another example is the treatment of bone
pain in advanced cancer, which can be addressed by
several different treatment approaches (radiation,
surgery, bisphophonates); thus, the latency of effect
onset (days versus weeks) becomes critically important
in deciding which treatment to use for patients with
limited lifespan.
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Longitudinal assessment is also required to deter-
mine the duration of effects. Many agents, especially
agents directed at symptom reduction, work “for a
while.” Their beneﬁcial effects may taper off for
several reasons (development of drug resistance,
increasing tolerance to the agent, etc.). Patients may
also recalibrate the trade-off between the positive ben-
eﬁts of the agent and its negative side effects or the
inconvenience of taking the agent. Only a subset of
agents that are effective will be so over time and will
continue to be used by the target population. To be
able to describe the duration of effects, depending on
the agent to be evaluated, will require evaluation over
a period of weeks or months. Here is where missing
data become an appreciable problem, mandating a
very brief assessment and substantial planning on how
this assessment is to be collected. Often, research
nurses or data managers collect such data by tele-
phone, especially when patients/clinical condition no
longer requires routine clinic visits. Electronically
assisted assessments (computer or interactive voice
response systems) may help in the collection of these
long-term data.
Conclusions
Patient-reported outcomes assessment builds on a long
and empirically based approach to measurement. It is
not “new,” nor “soft,” nor “subjective” in the negative
sense with which that term is used to describe the data.
Rather, effective PRO assessment stems from a concep-
tual framework that explains and predicts patient
behavior. Instrument development is neither trivial nor
inexpensive. Done correctly, it involves theoretical
explication, qualitative exploration, quantitative con-
ﬁrmation, and psychometric support. Instrument
developers need to be clear about what they want to
know, from whom they want to know it and why, if
what they learned is credible, and whether they can
interpret what they learned in the context of the
research objectives. High-quality PRO assessment data
will take on increasing importance as they become
more central in the health-care delivery arena.
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